⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19173 | 0.68 | — | — | |
| SCHEMBL312692 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL6894527 | 0.67 | PDE10A (0.45) | — | |
| SCHEMBL31338725 | 0.67 | PDE10A (0.45) | — | |
| SCHEMBL31674379 | 0.67 | PDE10A (0.45) | — | |
| SCHEMBL15830149 | 0.67 | — | — | |
| SCHEMBL1440869 | 0.65 | DYRK1A (0.49) | — | |
| SCHEMBL5435761 | 0.64 | DYRK1A (0.61) | — | |
| SCHEMBL14432725 | 0.64 | TGFBR1 (0.35) | — | |
| SCHEMBL4789377 | 0.64 | DYRK1A (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 330 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210220408-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2021-07-22 | — | — | US | claimed |
| EP-3847159-A2 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE | Magenta Therapeutics, Inc. (US) | 2021-07-14 | — | — | EP | claimed |
| EP-3078738-B1 | WNT PATHWAY STIMULATION IN REPROGRAMMING SOMATIC CELLS | WHITEHEAD INST BIOMEDICAL RES (US) | 2020-05-20 | — | — | EP | claimed |
| WO-2011033094-A1 | SCHEDULE OF ADMINISTRATION OF BENZAZOLE DERIVATIVES IN THE TREATMENT OF LEUKEMIAS | 4SC AG (DE) | 2011-03-24 | — | — | WO | claimed |
| EP-1996583-A1 | THIAZOLES AS NF-KB INHIBITORS (PROTEASOME INHIBITORS) | 4SC AG (DE) | 2008-12-03 | — | — | EP | claimed |
| WO-2007104558-A1 | THIAZOLES AS NF-KB INHIBITORS (PROTEASOME INHIBITORS) | 4SC AG (DE) | 2007-09-20 | — | — | WO | claimed |
| US-20070219190-A1 | Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2007-09-20 | — | — | US | claimed |
| EP-1834954-A1 | Thiazoles as NF-kB Inhibitors (proteasome inhibitors) | 4SC AG (DE) | 2007-09-19 | — | — | EP | claimed |
| US-12497568-B2 | Upgrading of bio-oil using ammonia | UNIVERSITY OF SOUTH CAROLINA (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250243190-A1 | NEW DEUTERATED RORGAMMA/RORGAMMAT INVERSE AGONISTS | IMMUNIC AG (DE) | 2025-07-31 | — | — | US | disclosed |
| US-12351822-B2 | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto | UNIVERSITY OF HOUSTON SYSTEM (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4508049-A1 | DEUTERATED RORGAMMA/RORGAMMAT INVERSE AGONISTS | Immunic AG (DE) | 2025-02-19 | — | — | EP | disclosed |
| US-20240368145-A1 | METHODS FOR TREATING CANCER | IMMUNIC AG (DE) | 2024-11-07 | — | — | US | disclosed |
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-31 | — | — | US | disclosed |
| US-6960583-B2 | Pyrazolotriazines as CRF antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20040176376-A1 | Pyrazolotriazines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-09 | — | — | US | disclosed |
| US-6730465-B2 | Color photographic element containing a heterocyclic dye-forming coupler | EASTMAN KODAK COMPANY | 2004-05-04 | — | — | US | disclosed |
| US-20030207219-A1 | Color photographic element containing a heterocyclic dye-forming coupler | EASTMAN KODAK COMPANY | 2003-11-06 | — | — | US | disclosed |
| EP-1345077-A2 | Colour photographic element containing a heterocyclic dye-forming coupler | EASTMAN KODAK COMPANY (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20020147338-A1 | Pyrazolotriazines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-10-10 | — | — | US | disclosed |